Paladin Labs Inc. announces approval of Wakix in Canada for the treatment of excessive daytime sleepiness or cataplexy.
Paladin plans to work collaboratively with the Canadian Agency for Drugs and Technologies in Health (CADTH) and the Institut national d'excellence en santé et en services sociaux (INESSS) to ensure patients have access to Wakix as soon as possible.
In 2018 Endo Ventures Limited, a subsidiary of Endo International plc, entered into an agreement with Bioprojet SCR to register, commercialize, and distribute pitolisant on an exclusive basis in Canada. Paladin Labs Inc., an operating company of Endo, is commercializing pitolisant in Canada.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
4 mins